What's Next In: Packaging - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

What's Next In: Packaging


Pharmaceutical Technology


A frustrated baby boomer will invent a child-resistant cap that keeps toddlers out, yet allows adults easy access.

There was a time when the credo of the boomer generation was "Don't trust anyone over 30." Now long past 30, today's boomers still have an attitude about age. They're going to ignore it as long as possible. However, as boomers push 50 or 60 and begin taking more prescription drugs for chronic conditions and dietary to maintain or improve their health, it's only a matter of time before someone comes up with a concept that ends the struggle to open child-resistant containers.

Hallie Forcinio, contributing editor,
Pharmaceutical Technology

Industry experts give their predictions for the next 30 years. Read Editor-in-Chief Michelle Hoffman's introduction here. See what's next in:

Strategy and Regulation
Outsourcing
Solid-Dosage Formulation
Ingredients
Drug Delivery
Packaging
Analytical Testing
Information Technology


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here